TSMC Stake Sale Sends Vanguard Semiconductor Shares Lower 
Alphabet Raises Record $3.6 Billion in Yen Bonds to Support AI Expansion 
YouTube and Snap Settle School District Mental Health Lawsuit Ahead of Major Social Media Trial 
CXMT Forecasts Record Revenue Growth as Global DRAM Prices Surge 
Anthropic Nears $30 Billion Funding Round at $900 Billion Valuation 
Samsung Shares Drop as Labor Union Confirms Planned Strike 
Standard Chartered Targets Higher Profitability With Major Workforce Cuts 
Applied Materials Forecasts Strong Q3 Revenue as AI Chip Demand Accelerates 
Asia-Pacific Banks Brace for Rising Credit Risks Amid Iran Conflict 
Standard Chartered Appoints Manus Costello as New CFO Amid Leadership Reshuffle 
FTC Antitrust Probe Targets Arm Holdings Over Chip Licensing Practices 
BlackRock-Led GCC Infrastructure Partnership Targets $30 Billion Investment 
Sonova Beats Profit Forecasts Despite Cochlear Implant Weakness 
OpenAI Wins Elon Musk Lawsuit as Jury Rejects Claims Over AI Mission 
US-China Trade Talks Sideline Chip Export Controls as Nvidia China Sales Draw Attention 
LIVONIA, Mich., Sept. 22, 2016 -- Gemphire Therapeutics Inc. (Nasdaq:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for the treatment of dyslipidemia, a serious medical condition that increases the risk of life threatening cardiovascular disease, and NAFLD/NASH (nonalcoholic fatty liver disease), today announced that Mina Sooch, President and Chief Executive Officer, will present a corporate overview at the Ladenburg Thalmann 2016 Healthcare Conference, being held at the Sofitel New York Hotel, on Tuesday, September 27.
| Presentation Details: | |
| Date: | Tuesday, September 27 |
| Time: | 2:00pm Eastern Time |
| Location: | Sofitel New York Hotel, Trocadero Room |
The presentation slides will be available immediately prior to and for 90 days following the presentation on the Investors and Media page of Gemphire’s website at http://ir.gemphire.com.
About Gemphire
Gemphire is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for the treatment of dyslipidemia, a serious medical condition that increases the risk of life threatening cardiovascular disease, and NAFLD/NASH (nonalcoholic fatty liver disease). Please visit www.gemphire.com for more information.
Contact: Andrew McDonald, Ph.D. LifeSci Advisors, LLC (646) 597-6987 Jeff Mathiesen, CFO Gemphire Therapeutics (734)-245-1700
